董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William Chase | 男 | Independent Director | 58 | 33.25万 | 0.24 | 2026-06-01 |
| Steve Mizell | 男 | Independent Director | 66 | 33.00万 | 0.24 | 2026-06-01 |
| Sarah Krevans | 女 | Independent Director | 67 | 32.25万 | 未持股 | 2026-06-01 |
| Joshua Ofman | 男 | President and Director and Chief Executive Officer | 62 | 431.86万 | 未持股 | 2026-06-01 |
| Gregory Summe | 男 | Independent Director and Chairperson of the Board | 69 | 37.75万 | 0.38 | 2026-06-01 |
| Robert Ragusa | 男 | Director | 66 | 809.44万 | 29.99 | 2026-06-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Aaron Freidin | 男 | Chief Financial Officer | 47 | 313.15万 | 12.50 | 2026-06-01 |
| Joshua Ofman | 男 | President and Director and Chief Executive Officer | 62 | 431.86万 | 未持股 | 2026-06-01 |
董事简历
中英对照 | 中文 | 英文- William Chase
-
William Chase，自2023年4月起担任Intellia Therapeutics，Inc.董事会成员。Chase先生于2018年10月至2019年7月在艾伯维公司（“艾伯维”）担任财务和行政执行副总裁，在此之前于2012年至2018年担任执行副总裁兼首席财务官。在这些职位上，他监督了所有金融、投资者和信息技术活动，并在艾伯维的许可和收购活动中发挥了关键的战略作用。在任职于艾伯维之前，他曾在雅培（“雅培”）担任多个财务和战略职位，包括负责许可与收购的公司副总裁、公司副总裁、财务主管，以及雅培国际公司的部门副总裁兼财务总监。他目前在Parexel International Corporation董事会任职。Chase先生拥有伊利诺伊大学金融学学士学位和芝加哥大学工商管理硕士学位。
William Chase,has served as a member of Grail, Inc. Board since June 2024. Mr. Chase most recently served for 7 years in roles as Executive Vice President, Finance and Administration and Executive Vice President and Chief Financial Officer at AbbVie Inc. ("AbbVie") from October 2018 until July 2019, where he oversaw all financial, investor, and IT activities and played a critical role in the development of the company's strategy and licensing and acquisition actions. Prior to AbbVie, Mr. Chase served nearly 25 years in positions of increasing responsibility at Abbott Laboratories, including roles as Corporate Vice President, Licensing & Acquisitions, Corporate Vice President and Treasurer, and Controller, Abbott International. He currently serves as a director and as chair of the audit committee on the boards of each of Intellia Therapeutics, Inc., a publicly-traded biotechnology company, since April 2023, and Parexel International, a privately-held biopharmaceutical services company, since November 2021. Mr. Chase holds a B.S. from the University of Illinois and an M.B.A. from the University of Chicago Booth School of Business. - William Chase，自2023年4月起担任Intellia Therapeutics，Inc.董事会成员。Chase先生于2018年10月至2019年7月在艾伯维公司（“艾伯维”）担任财务和行政执行副总裁，在此之前于2012年至2018年担任执行副总裁兼首席财务官。在这些职位上，他监督了所有金融、投资者和信息技术活动，并在艾伯维的许可和收购活动中发挥了关键的战略作用。在任职于艾伯维之前，他曾在雅培（“雅培”）担任多个财务和战略职位，包括负责许可与收购的公司副总裁、公司副总裁、财务主管，以及雅培国际公司的部门副总裁兼财务总监。他目前在Parexel International Corporation董事会任职。Chase先生拥有伊利诺伊大学金融学学士学位和芝加哥大学工商管理硕士学位。
- William Chase,has served as a member of Grail, Inc. Board since June 2024. Mr. Chase most recently served for 7 years in roles as Executive Vice President, Finance and Administration and Executive Vice President and Chief Financial Officer at AbbVie Inc. ("AbbVie") from October 2018 until July 2019, where he oversaw all financial, investor, and IT activities and played a critical role in the development of the company's strategy and licensing and acquisition actions. Prior to AbbVie, Mr. Chase served nearly 25 years in positions of increasing responsibility at Abbott Laboratories, including roles as Corporate Vice President, Licensing & Acquisitions, Corporate Vice President and Treasurer, and Controller, Abbott International. He currently serves as a director and as chair of the audit committee on the boards of each of Intellia Therapeutics, Inc., a publicly-traded biotechnology company, since April 2023, and Parexel International, a privately-held biopharmaceutical services company, since November 2021. Mr. Chase holds a B.S. from the University of Illinois and an M.B.A. from the University of Chicago Booth School of Business.
- Steve Mizell
-
Steve Mizell自2024年6月起担任董事会成员。Mizell先生是默克制药公司的前任执行副总裁兼首席人力资源官，该公司于2018年10月任职至2024年7月1日退休。他负责全球超过68,000名员工的人才获取和发展、员工健康和健康、总奖励以及人力资本管理。Mizell Previoly先生于2004年至2018年期间担任孟山都公司执行副总裁兼首席人力资源官，在那里他为全球超过20,000名员工创造了一个行业领先的工作场所。在此之前，Mizell先生曾担任AdvancePCS Inc.的高级副总裁兼首席企业薪酬官，在此之前，他曾在能源、国防、制造、通信和技术领域的公司担任多个关键的人力薪酬管理职务。他目前自2020年2月起担任上市安全产品公司Allegion Plc.的董事会成员，自2021年3月起担任上市汽车零售商Group 1 Automotive, Inc.的董事会成员，并获得了董事证书来自全国公司董事协会。
Steve Mizell has served as a member of Board since June 2024. Mr. Mizell is the former Executive Vice President and Chief Human Resources Officer at Merck & Co., Inc., where was employed from October 2018 until his retirement on July 1, 2024. He was responsible for talent acquisition and development, employee health and llness, total rewards, and human capital management for over 68,000 employees across the world. Mr. Mizell previoly served as Executive Vice President & Chief Human Resources Officer at Monsanto Company from 2004 until 2018, where he created an industry leading workplace for more than 20,000 employees globally. Before that, Mr. Mizell served as Senior Vice President and Chief Corporate Resources Officer for AdvancePCS Inc. and previo to that held several key human Resources management roles at companies across the energy, defense, manufacturing, communications and technology sectors. He currently serves on the boards of Allegion Plc., a publicly traded security products company, since February 2020, and Group 1 Automotive, Inc., a publicly traded automotive retailer since March 2021, and has earned a Directorship Certification from the National Association of Corporate Directors. Mr. Mizell holds a B.S. from Georgia Institute of Technology and an M.S. from Carnegie Mellon University. - Steve Mizell自2024年6月起担任董事会成员。Mizell先生是默克制药公司的前任执行副总裁兼首席人力资源官，该公司于2018年10月任职至2024年7月1日退休。他负责全球超过68,000名员工的人才获取和发展、员工健康和健康、总奖励以及人力资本管理。Mizell Previoly先生于2004年至2018年期间担任孟山都公司执行副总裁兼首席人力资源官，在那里他为全球超过20,000名员工创造了一个行业领先的工作场所。在此之前，Mizell先生曾担任AdvancePCS Inc.的高级副总裁兼首席企业薪酬官，在此之前，他曾在能源、国防、制造、通信和技术领域的公司担任多个关键的人力薪酬管理职务。他目前自2020年2月起担任上市安全产品公司Allegion Plc.的董事会成员，自2021年3月起担任上市汽车零售商Group 1 Automotive, Inc.的董事会成员，并获得了董事证书来自全国公司董事协会。
- Steve Mizell has served as a member of Board since June 2024. Mr. Mizell is the former Executive Vice President and Chief Human Resources Officer at Merck & Co., Inc., where was employed from October 2018 until his retirement on July 1, 2024. He was responsible for talent acquisition and development, employee health and llness, total rewards, and human capital management for over 68,000 employees across the world. Mr. Mizell previoly served as Executive Vice President & Chief Human Resources Officer at Monsanto Company from 2004 until 2018, where he created an industry leading workplace for more than 20,000 employees globally. Before that, Mr. Mizell served as Senior Vice President and Chief Corporate Resources Officer for AdvancePCS Inc. and previo to that held several key human Resources management roles at companies across the energy, defense, manufacturing, communications and technology sectors. He currently serves on the boards of Allegion Plc., a publicly traded security products company, since February 2020, and Group 1 Automotive, Inc., a publicly traded automotive retailer since March 2021, and has earned a Directorship Certification from the National Association of Corporate Directors. Mr. Mizell holds a B.S. from Georgia Institute of Technology and an M.S. from Carnegie Mellon University.
- Sarah Krevans
-
Sarah Krevans自2024年10月21日起担任董事会成员。Krevans女士是Sutter Health的前总裁兼首席执行官，该公司总部位于北加州，不以盈利为目的，她在2016年至2022年期间担任该公司的首席执行官。她负责Sutter Health由14,000名临床医生组成的综合网络、24家医院、门诊服务、研究设施以及家庭健康和临终关怀。Previoly，Krevans女士曾担任Sutter Health Sacramento Sierra地区的首席运营官和总裁。她还曾在Kaiser Permanente担任执行职务，并担任缅因州医疗服务局副局长和医疗补助、健康规划和许可项目代理主任。Krevans女士自2021年以来一直担任Acacium集团的董事会成员，并担任CaringBridge的主席，她自2022年以来一直担任该公司的董事。她还担任Alignment Health Plan的顾问委员会成员。Krevans女士曾在许多非盈利组织的董事会任职，并于2022年担任加州医院协会主席，并于2016年至2022年担任董事。Krevans女士获得了加州大学伯克利分校的BINES管理和公共卫生硕士学位，并获得了波士顿大学的学士学位。
Sarah Krevans,has served as a member of Grail, Inc. Board since October 21, 2024. Ms. Krevans is the former President and CEO of Sutter Health, a Northern California based not-for-profit, where she served as CEO from 2016 until 2022. She was responsible for Sutter Health's integrated network of 14,000 clinicians, 24 hospitals, outpatient services, research facilities, and home health and hospice care. Previously, Ms. Krevans served as chief operating officer and president of the Sutter Health Sacramento Sierra Region. She also held executive roles at Kaiser Permanente and served as deputy director of Maine's Bureau of Medical Services and acting director of Medicaid, health planning and licensure programs. Ms. Krevans has served as a Board Member for The Acacium Group since 2021 and is the Chair for CaringBridge, where she has served as a director since 2022. She has also served on Boards of many not-for-profit organizations and served as Chair of the California Hospital Association in 2022 and as a director from 2016 until 2022. Ms. Krevans earned master's degrees in business administration and in public health from the University of California, Berkeley, and a bachelor's degree from Boston University. - Sarah Krevans自2024年10月21日起担任董事会成员。Krevans女士是Sutter Health的前总裁兼首席执行官，该公司总部位于北加州，不以盈利为目的，她在2016年至2022年期间担任该公司的首席执行官。她负责Sutter Health由14,000名临床医生组成的综合网络、24家医院、门诊服务、研究设施以及家庭健康和临终关怀。Previoly，Krevans女士曾担任Sutter Health Sacramento Sierra地区的首席运营官和总裁。她还曾在Kaiser Permanente担任执行职务，并担任缅因州医疗服务局副局长和医疗补助、健康规划和许可项目代理主任。Krevans女士自2021年以来一直担任Acacium集团的董事会成员，并担任CaringBridge的主席，她自2022年以来一直担任该公司的董事。她还担任Alignment Health Plan的顾问委员会成员。Krevans女士曾在许多非盈利组织的董事会任职，并于2022年担任加州医院协会主席，并于2016年至2022年担任董事。Krevans女士获得了加州大学伯克利分校的BINES管理和公共卫生硕士学位，并获得了波士顿大学的学士学位。
- Sarah Krevans,has served as a member of Grail, Inc. Board since October 21, 2024. Ms. Krevans is the former President and CEO of Sutter Health, a Northern California based not-for-profit, where she served as CEO from 2016 until 2022. She was responsible for Sutter Health's integrated network of 14,000 clinicians, 24 hospitals, outpatient services, research facilities, and home health and hospice care. Previously, Ms. Krevans served as chief operating officer and president of the Sutter Health Sacramento Sierra Region. She also held executive roles at Kaiser Permanente and served as deputy director of Maine's Bureau of Medical Services and acting director of Medicaid, health planning and licensure programs. Ms. Krevans has served as a Board Member for The Acacium Group since 2021 and is the Chair for CaringBridge, where she has served as a director since 2022. She has also served on Boards of many not-for-profit organizations and served as Chair of the California Hospital Association in 2022 and as a director from 2016 until 2022. Ms. Krevans earned master's degrees in business administration and in public health from the University of California, Berkeley, and a bachelor's degree from Boston University.
- Joshua Ofman
-
Joshua Ofman自2021年6月起担任公司总裁，previoly自2021年11月至2022年6月担任公司首席医疗官，自2020年6月至2021年8月担任公司首席医疗官和对外事务主管，自2019年6月至2020年1月担任公司战略和对外事务主管。Ofman博士曾在两家私营生物技术公司的董事会任职。Previoly表示，Ofman博士在安进工作了超过15年，他最后一次担任的是全球价值、准入和政策高级副总裁。在此之前，Ofman博士是加州大学洛杉矶分校（简称“UCLA”）医学院Cedars Sinai医学中心医学和健康服务研究部的教员，并担任Zynx Health，Inc.的高级副总裁。Ofman博士拥有加州大学伯克利分校的历史和科学哲学学士学位、加州大学欧文分校医学院的医学博士学位和加州大学洛杉矶分校公共卫生学院的MSHS学位。
Joshua Ofman,has served as Grail, Inc. President since June 2021 and previously served as Grail, Inc. Chief Medical Officer from November 2021 until June 2022, as Grail, Inc. Chief Medical Officer and Head of External Affairs from June 2020 until August 2021, and as Chief of Corporate Strategy and External Affairs from June 2019 until January 2020. On March 10, 2026, Dr. Ofman was also appointed to serve as Grail, Inc. Chief Executive Officer, effective June 1, 2026. Dr. Ofman has previously served on the Board of Directors of two privately-held biotechnology companies. Previously, Dr. Ofman spent more than 15 years at Amgen, where he most recently held the role of Senior Vice President, Global Value, Access and Policy. Prior to that, Dr. Ofman was a faculty member in the Department of Medicine and Health Services Research at University of California, Los Angeles ("UCLA") School of Medicine, Division of Digestive Diseases at Cedars-Sinai Medical Center, as well as Senior Vice President of Zynx Health Inc. Dr. Ofman holds a B.A. in history and philosophy of science from the University of California, Berkeley, an M.D. from the University of California, Irvine, School of Medicine, and an MSHS from the UCLA School of Public Health. - Joshua Ofman自2021年6月起担任公司总裁，previoly自2021年11月至2022年6月担任公司首席医疗官，自2020年6月至2021年8月担任公司首席医疗官和对外事务主管，自2019年6月至2020年1月担任公司战略和对外事务主管。Ofman博士曾在两家私营生物技术公司的董事会任职。Previoly表示，Ofman博士在安进工作了超过15年，他最后一次担任的是全球价值、准入和政策高级副总裁。在此之前，Ofman博士是加州大学洛杉矶分校（简称“UCLA”）医学院Cedars Sinai医学中心医学和健康服务研究部的教员，并担任Zynx Health，Inc.的高级副总裁。Ofman博士拥有加州大学伯克利分校的历史和科学哲学学士学位、加州大学欧文分校医学院的医学博士学位和加州大学洛杉矶分校公共卫生学院的MSHS学位。
- Joshua Ofman,has served as Grail, Inc. President since June 2021 and previously served as Grail, Inc. Chief Medical Officer from November 2021 until June 2022, as Grail, Inc. Chief Medical Officer and Head of External Affairs from June 2020 until August 2021, and as Chief of Corporate Strategy and External Affairs from June 2019 until January 2020. On March 10, 2026, Dr. Ofman was also appointed to serve as Grail, Inc. Chief Executive Officer, effective June 1, 2026. Dr. Ofman has previously served on the Board of Directors of two privately-held biotechnology companies. Previously, Dr. Ofman spent more than 15 years at Amgen, where he most recently held the role of Senior Vice President, Global Value, Access and Policy. Prior to that, Dr. Ofman was a faculty member in the Department of Medicine and Health Services Research at University of California, Los Angeles ("UCLA") School of Medicine, Division of Digestive Diseases at Cedars-Sinai Medical Center, as well as Senior Vice President of Zynx Health Inc. Dr. Ofman holds a B.A. in history and philosophy of science from the University of California, Berkeley, an M.D. from the University of California, Irvine, School of Medicine, and an MSHS from the UCLA School of Public Health.
- Gregory Summe
-
Gregory Summe, Glen Capital Partners， LLC（另类资产投资基金）的管理合伙人和创始人。NXP Semiconductors（纳斯达克上市的半导体制造商）董事（2010年至今）；提名及企业管治委员会成员（主席）；（在2015年被NXP Semiconductors收购之前，2010年至2015年担任Freescale Semiconductor， Inc.董事，2013年至2015年担任董事长；2015年至今更名为NXP Semiconductors）。Avantor, Inc.（纽约证券交易所上市的化学和材料公司）董事（2020年至今）；提名及公司管治委员会成员（主席）及薪酬及人力资源委员会成员。Virgin Orbit Holdings, Inc.（纳斯达克上市的卫星发射服务提供商）董事（2021年至今）；审计委员会成员（主席）及薪酬委员会成员。2009年至2014年，担任凯雷集团（一家纳斯达克上市的全球资产管理公司）全球收购业务的董事总经理兼副董事长。PerkinElmer, Inc.（纽约证券交易所上市的生命科学设备和服务开发商和生产商）的前董事长、首席执行官和总裁（1998-2009）。NextGen Acquisition Corporation I前联合董事长和联合创始人；NextGen Acquisition Corporation II，分别是纳斯达克上市的特殊目的收购公司（SPAC）（2020-2021）。LMI Aerospace（纳斯达克上市的航空航天结构设计和供应商）前董事（2014年至2017年）。
Gregory Summe,has served as Chair of Grail, Inc. Board since June 2024. Mr. Summe is the Founder of investment fund Glen Capital Partners LLC and has served as the Managing Partner since June 2014. Mr. Summe previously served as Managing Director and Vice Chairman of Global Buyout at The Carlyle Group from October 2009 until June 2014. Prior to The Carlyle Group, Mr. Summe served for over a decade as Chairman, CEO, and President of PerkinElmer, Inc., a leading diagnostics and life sciences company. He also served as a Senior Advisor at Goldman Sachs Capital Partners and was the President of AlliedSignal, Inc.'s Automotive, Jet Engine, and General Avionics businesses. Previously, he was the General Manager of General Electric Commercial Motors and a Partner at McKinsey and Company. He currently serves on the boards of NXP Semiconductors N.V., a publicly-traded semiconductor company, since December 2015, Avantor, Inc., a publicly-traded Life Sciences company, since May 2020, Wheels Up Experience, Inc., a publicly traded aviation company since September 2024 and is a Senior Advisor at Star Mountain Capital, LLC. Mr. Summe previously served on the board of the State Street Corporation, a publicly-traded financial services company from 2001 until 2025, Virgin Orbit Holdings, Inc., a publicly-traded space launch services company, from January 2022 until August 2023, and on the boards of NextGen Acquisition Corp I & II from July 2020 until December 2021. Mr. Summe holds a B.S. from the University of Kentucky, an M.S. from the University of Cincinnati, and an M.B.A. from the Wharton School of the University of Pennsylvania. - Gregory Summe, Glen Capital Partners， LLC（另类资产投资基金）的管理合伙人和创始人。NXP Semiconductors（纳斯达克上市的半导体制造商）董事（2010年至今）；提名及企业管治委员会成员（主席）；（在2015年被NXP Semiconductors收购之前，2010年至2015年担任Freescale Semiconductor， Inc.董事，2013年至2015年担任董事长；2015年至今更名为NXP Semiconductors）。Avantor, Inc.（纽约证券交易所上市的化学和材料公司）董事（2020年至今）；提名及公司管治委员会成员（主席）及薪酬及人力资源委员会成员。Virgin Orbit Holdings, Inc.（纳斯达克上市的卫星发射服务提供商）董事（2021年至今）；审计委员会成员（主席）及薪酬委员会成员。2009年至2014年，担任凯雷集团（一家纳斯达克上市的全球资产管理公司）全球收购业务的董事总经理兼副董事长。PerkinElmer, Inc.（纽约证券交易所上市的生命科学设备和服务开发商和生产商）的前董事长、首席执行官和总裁（1998-2009）。NextGen Acquisition Corporation I前联合董事长和联合创始人；NextGen Acquisition Corporation II，分别是纳斯达克上市的特殊目的收购公司（SPAC）（2020-2021）。LMI Aerospace（纳斯达克上市的航空航天结构设计和供应商）前董事（2014年至2017年）。
- Gregory Summe,has served as Chair of Grail, Inc. Board since June 2024. Mr. Summe is the Founder of investment fund Glen Capital Partners LLC and has served as the Managing Partner since June 2014. Mr. Summe previously served as Managing Director and Vice Chairman of Global Buyout at The Carlyle Group from October 2009 until June 2014. Prior to The Carlyle Group, Mr. Summe served for over a decade as Chairman, CEO, and President of PerkinElmer, Inc., a leading diagnostics and life sciences company. He also served as a Senior Advisor at Goldman Sachs Capital Partners and was the President of AlliedSignal, Inc.'s Automotive, Jet Engine, and General Avionics businesses. Previously, he was the General Manager of General Electric Commercial Motors and a Partner at McKinsey and Company. He currently serves on the boards of NXP Semiconductors N.V., a publicly-traded semiconductor company, since December 2015, Avantor, Inc., a publicly-traded Life Sciences company, since May 2020, Wheels Up Experience, Inc., a publicly traded aviation company since September 2024 and is a Senior Advisor at Star Mountain Capital, LLC. Mr. Summe previously served on the board of the State Street Corporation, a publicly-traded financial services company from 2001 until 2025, Virgin Orbit Holdings, Inc., a publicly-traded space launch services company, from January 2022 until August 2023, and on the boards of NextGen Acquisition Corp I & II from July 2020 until December 2021. Mr. Summe holds a B.S. from the University of Kentucky, an M.S. from the University of Cincinnati, and an M.B.A. from the Wharton School of the University of Pennsylvania.
- Robert Ragusa
-
Robert Ragusa，自2016年11月起担任Twist Bioscience Corporation董事会成员。Ragusa先生目前是GRAIL，LLC的首席执行官。（“GRAIL”）是一家专注于多种癌症早期检测的医疗保健公司。他自2021年10月起担任GRAIL首席执行官。Ragusa先生于2013年12月至2021年10月担任Illumina, Inc.的首席运营官。在加入Illumina, Inc.之前，2010年4月至2013年11月，Ragusa先生在Accuray Incorporated担任全球运营和服务执行副总裁。Ragusa先生拥有康涅狄格大学生物医学和电气工程学士学位和工商管理硕士学位，以及卡内基-梅隆大学生物医学和电气工程硕士学位。
Robert Ragusa,has served as Grail, Inc. Chief Executive Officer since October 2021 and as a member of Grail, Inc. Board since June 2024. Mr. Ragusa was previously Chief Operations Officer for Illumina from December 2013 until October 2021, where he was responsible for the company's operations serving clinical and research customers. Prior to joining Illumina, Mr. Ragusa was Executive Vice President of Engineering and Global Operations at Accuray Incorporated from April 2010 until December 2013, a radiation oncology company, where he and his team were responsible for the development, manufacturing and distribution of innovative precision treatment solutions. Mr. Ragusa also previously served as Senior Vice President of Global Operations for Applied Biosystems from 1997 until 2005. Mr. Ragusa currently serves on the Board of Directors for Twist Bioscience Corporation, a publicly-held synthetic biology company, since December 2016. Mr. Ragusa holds a B.S. in electrical engineering and an M.B.A. from the University of Connecticut as well as an M.S. in biomedical and electrical engineering from Carnegie Mellon University. - Robert Ragusa，自2016年11月起担任Twist Bioscience Corporation董事会成员。Ragusa先生目前是GRAIL，LLC的首席执行官。（“GRAIL”）是一家专注于多种癌症早期检测的医疗保健公司。他自2021年10月起担任GRAIL首席执行官。Ragusa先生于2013年12月至2021年10月担任Illumina, Inc.的首席运营官。在加入Illumina, Inc.之前，2010年4月至2013年11月，Ragusa先生在Accuray Incorporated担任全球运营和服务执行副总裁。Ragusa先生拥有康涅狄格大学生物医学和电气工程学士学位和工商管理硕士学位，以及卡内基-梅隆大学生物医学和电气工程硕士学位。
- Robert Ragusa,has served as Grail, Inc. Chief Executive Officer since October 2021 and as a member of Grail, Inc. Board since June 2024. Mr. Ragusa was previously Chief Operations Officer for Illumina from December 2013 until October 2021, where he was responsible for the company's operations serving clinical and research customers. Prior to joining Illumina, Mr. Ragusa was Executive Vice President of Engineering and Global Operations at Accuray Incorporated from April 2010 until December 2013, a radiation oncology company, where he and his team were responsible for the development, manufacturing and distribution of innovative precision treatment solutions. Mr. Ragusa also previously served as Senior Vice President of Global Operations for Applied Biosystems from 1997 until 2005. Mr. Ragusa currently serves on the Board of Directors for Twist Bioscience Corporation, a publicly-held synthetic biology company, since December 2016. Mr. Ragusa holds a B.S. in electrical engineering and an M.B.A. from the University of Connecticut as well as an M.S. in biomedical and electrical engineering from Carnegie Mellon University.
高管简历
中英对照 | 中文 | 英文- Aaron Freidin
Aaron Freidin自2021年11月起担任首席财务官，previoly自2016年起在GRAIL担任多个职务，包括2021年1月至2021年11月的财务高级副总裁，2018年6月至2021年1月的财务副总裁，以及2016年8月至2018年6月的公司财务总监。Freidin Previoly先生曾在Counsyl担任副总裁兼公司财务总监，领导会计、报告、设施和采购职能。在此之前，Freidin先生在Cepheid领导SEC报告和收入职能，并在PricewaterhoeCoopers LLP管理跨国和跨职能客户服务团队。Freidin先生拥有超过24年的财务和会计经验。Freidin先生是一名注册会计师（非在职），拥有加州大学圣克鲁斯分校biness管理学士学位。
Aaron Freidin,has served as Grail, Inc. Chief Financial Officer since November 2021 and previously served in various roles at GRAIL since 2016, including Senior Vice President of Finance from January 2021 until November 2021, Vice President of Finance from June 2018 until January 2021, and Corporate Controller from August 2016 until June 2018. Mr. Freidin previously served as VP, Corporate Controller at Counsyl, where he led the Accounting, Reporting, Facilities and Procurement functions. Before this, Mr. Freidin led the SEC Reporting and Revenue functions at Cepheid, and managed multinational and cross-functional client service teams at PricewaterhouseCoopers LLP. Mr. Freidin has over 24 years of finance and accounting experience. Mr. Freidin is a Certified Public Accountant (Inactive) and holds a B.A. in business management from the University of California, Santa Cruz.- Aaron Freidin自2021年11月起担任首席财务官，previoly自2016年起在GRAIL担任多个职务，包括2021年1月至2021年11月的财务高级副总裁，2018年6月至2021年1月的财务副总裁，以及2016年8月至2018年6月的公司财务总监。Freidin Previoly先生曾在Counsyl担任副总裁兼公司财务总监，领导会计、报告、设施和采购职能。在此之前，Freidin先生在Cepheid领导SEC报告和收入职能，并在PricewaterhoeCoopers LLP管理跨国和跨职能客户服务团队。Freidin先生拥有超过24年的财务和会计经验。Freidin先生是一名注册会计师（非在职），拥有加州大学圣克鲁斯分校biness管理学士学位。
- Aaron Freidin,has served as Grail, Inc. Chief Financial Officer since November 2021 and previously served in various roles at GRAIL since 2016, including Senior Vice President of Finance from January 2021 until November 2021, Vice President of Finance from June 2018 until January 2021, and Corporate Controller from August 2016 until June 2018. Mr. Freidin previously served as VP, Corporate Controller at Counsyl, where he led the Accounting, Reporting, Facilities and Procurement functions. Before this, Mr. Freidin led the SEC Reporting and Revenue functions at Cepheid, and managed multinational and cross-functional client service teams at PricewaterhouseCoopers LLP. Mr. Freidin has over 24 years of finance and accounting experience. Mr. Freidin is a Certified Public Accountant (Inactive) and holds a B.A. in business management from the University of California, Santa Cruz.
- Joshua Ofman
Joshua Ofman自2021年6月起担任公司总裁，previoly自2021年11月至2022年6月担任公司首席医疗官，自2020年6月至2021年8月担任公司首席医疗官和对外事务主管，自2019年6月至2020年1月担任公司战略和对外事务主管。Ofman博士曾在两家私营生物技术公司的董事会任职。Previoly表示，Ofman博士在安进工作了超过15年，他最后一次担任的是全球价值、准入和政策高级副总裁。在此之前，Ofman博士是加州大学洛杉矶分校（简称“UCLA”）医学院Cedars Sinai医学中心医学和健康服务研究部的教员，并担任Zynx Health，Inc.的高级副总裁。Ofman博士拥有加州大学伯克利分校的历史和科学哲学学士学位、加州大学欧文分校医学院的医学博士学位和加州大学洛杉矶分校公共卫生学院的MSHS学位。
Joshua Ofman,has served as Grail, Inc. President since June 2021 and previously served as Grail, Inc. Chief Medical Officer from November 2021 until June 2022, as Grail, Inc. Chief Medical Officer and Head of External Affairs from June 2020 until August 2021, and as Chief of Corporate Strategy and External Affairs from June 2019 until January 2020. On March 10, 2026, Dr. Ofman was also appointed to serve as Grail, Inc. Chief Executive Officer, effective June 1, 2026. Dr. Ofman has previously served on the Board of Directors of two privately-held biotechnology companies. Previously, Dr. Ofman spent more than 15 years at Amgen, where he most recently held the role of Senior Vice President, Global Value, Access and Policy. Prior to that, Dr. Ofman was a faculty member in the Department of Medicine and Health Services Research at University of California, Los Angeles ("UCLA") School of Medicine, Division of Digestive Diseases at Cedars-Sinai Medical Center, as well as Senior Vice President of Zynx Health Inc. Dr. Ofman holds a B.A. in history and philosophy of science from the University of California, Berkeley, an M.D. from the University of California, Irvine, School of Medicine, and an MSHS from the UCLA School of Public Health.- Joshua Ofman自2021年6月起担任公司总裁，previoly自2021年11月至2022年6月担任公司首席医疗官，自2020年6月至2021年8月担任公司首席医疗官和对外事务主管，自2019年6月至2020年1月担任公司战略和对外事务主管。Ofman博士曾在两家私营生物技术公司的董事会任职。Previoly表示，Ofman博士在安进工作了超过15年，他最后一次担任的是全球价值、准入和政策高级副总裁。在此之前，Ofman博士是加州大学洛杉矶分校（简称“UCLA”）医学院Cedars Sinai医学中心医学和健康服务研究部的教员，并担任Zynx Health，Inc.的高级副总裁。Ofman博士拥有加州大学伯克利分校的历史和科学哲学学士学位、加州大学欧文分校医学院的医学博士学位和加州大学洛杉矶分校公共卫生学院的MSHS学位。
- Joshua Ofman,has served as Grail, Inc. President since June 2021 and previously served as Grail, Inc. Chief Medical Officer from November 2021 until June 2022, as Grail, Inc. Chief Medical Officer and Head of External Affairs from June 2020 until August 2021, and as Chief of Corporate Strategy and External Affairs from June 2019 until January 2020. On March 10, 2026, Dr. Ofman was also appointed to serve as Grail, Inc. Chief Executive Officer, effective June 1, 2026. Dr. Ofman has previously served on the Board of Directors of two privately-held biotechnology companies. Previously, Dr. Ofman spent more than 15 years at Amgen, where he most recently held the role of Senior Vice President, Global Value, Access and Policy. Prior to that, Dr. Ofman was a faculty member in the Department of Medicine and Health Services Research at University of California, Los Angeles ("UCLA") School of Medicine, Division of Digestive Diseases at Cedars-Sinai Medical Center, as well as Senior Vice President of Zynx Health Inc. Dr. Ofman holds a B.A. in history and philosophy of science from the University of California, Berkeley, an M.D. from the University of California, Irvine, School of Medicine, and an MSHS from the UCLA School of Public Health.